Binding of [¹²⁵I]Shiga-like Toxin-1 to Human Endothelial Cells: Implications for the Pathogenesis of Shiga Toxin-associated Hemolytic Uremic Syndrome

References

• Bitzan M., Karch H. Indirect hemagglutination assay for diagnosis of Elscherichia coli 0157 infection in patients with hemolytic-uremic syndrome. J. Clin. Micro 1992; 30: 1174–1178
   PubMed Web of Science ®Google Scholar
• Boyd B., Lingwood C. Verotoxin receptor glycolipid in human renal tissue. Nephron 1989; 51: 207–210
   PubMedGoogle Scholar
• Calderwood S. B. J., Auclair F., Donohue-Rolfe A., Keusch G. T., Mekalanos J. J. Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli. Proc. Natl. Acad. 5ci. U.S.A 1987; 84: 4364–4368
   PubMed Web of Science ®Google Scholar
• De Grandis S., Ginsberg J., Toone M., Climie S., Friesen J., Brunton J. Nucleotide squence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J. Bacteriol 1987; 169: 4313–4319
   PubMed Web of Science ®Google Scholar
• Donohue-Rolfe A., Keusch G. T., Edson C., Thorley-Lawson D., Jacewicz M. Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies. J. Exp. Med 1984; 160: 1767–1781
   PubMed Web of Science ®Google Scholar
• Eiklid K., Olsnes S. Interaction of Shigella shigae cytotoxin with receptors on sensitive and insensitive cells. J. Receptor Res 1980; 1: 199–213
   PubMed Web of Science ®Google Scholar
• Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. Site of action of a Vero toxin (VT 2) from Escherichia coli 0157:H7 and of Shiga toxin on eukaryotic ribosomes. Eur. J. Biochem 1988; 171: 45–50
   PubMedGoogle Scholar
• Griffin P. M., Tauxe R. V. The epidemiology of infections caused by Escherichia coli 0157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol. Rev 1991; 13: 60–98
   PubMed Web of Science ®Google Scholar
• Head S. C., Karmali M. A., Lingwood C. A. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of A subunit function. J. Biol. Chem 1991; 266: 3617–3621
   PubMed Web of Science ®Google Scholar
• Jacewicz M., Clausen H., Nudelman E., Donohue-Rolfe A., Keusch G. T. Pathogenesis of Shigella diarrhea. XI. Isolation of Shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J. Exp. Med 1986; 163: 1391–1404
   PubMed Web of Science ®Google Scholar
• Kaye S. A., Louise C. B., Boyd B., Lingwood C. A., Obrig T. G. Shiga toxin-associated hemolytic uremic syndrome: Interleukin-1β enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect. Immun 1993; 61: 3886–3891
   PubMed Web of Science ®Google Scholar
• Kiarash A., Boyd B., Lingwood C. A. Glycosphingolipid receptor function is modified by fatty acid content. J. Biol. Chem 1994; 269: 11138–11146
   PubMed Web of Science ®Google Scholar
• Koster F., Boonpucknavig V., Sujaho S., Gilman R., Rahaman M. Renal histopathology in the hemolytic-uremic syndrome following shigellosis. Clin. Nephrol 1984; 21: 126–133
   PubMed Web of Science ®Google Scholar
• Koster F., Levin J., Walker L., Tung K. S. K., Gilman R. H., Rahaman M. M., Majid M. A. Hemolytic uremic syndrome after shigellosis. N. Engl. J. Med 1978; 298: 927–933
   PubMed Web of Science ®Google Scholar
• Lindberg A. A., Brown J. E., Stromberg N., Westling-Ryd M., Schultz J. E., Karlsson K. A. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J. Biol. Chem 1987; 262: 1779–1785
   PubMed Web of Science ®Google Scholar
• Lingwood C. A. Verotoxins and their glycolipid receptors. Adv. Lipid Res 1993; 25: 189–211
   PubMedGoogle Scholar
• Lingwood C. A. Verotoxin-binding in human renal sections. Nephron 1994; 66: 21–28
   PubMedGoogle Scholar
• Lingwood C. A., Law H., Richardson S., Petric M., Brunton J. L., Karmali M. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J. Biol. Chem 1987; 262: 8834–8839
   PubMed Web of Science ®Google Scholar
• Louise C. B., Obrig T. G. Shiga toxin-associated hemolytic-uremic syndrome: Combined cytotoxic effects of Shiga toxin, interleukin-1β. and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect. Immun 1991; 59: 4173–4179
   PubMed Web of Science ®Google Scholar
• Louise C. B., Obrig T. G. Shiga toxin-associated hemolytic uremic syndrome: Combined cytotoxic effects of Shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect. Immun 1992; 60: 1536–1543
   PubMed Web of Science ®Google Scholar
• Maloney M. M., Lingwood C. A. CD19 has a potential CD77 (globotriaosyl ceramidel-binding site with sequence similarity to verotoxin 8–subunits: Implications of molecular mimicry for B cell activation and enterohemorrhagic E. coli pathogenesis. J. Exp. Med 1994; 180: 191–201
   PubMed Web of Science ®Google Scholar
• Marques L., Moore M., Wells J., Wachsmuth I. K., O'Brien A. D. Production of Shiga-like toxin by Escherichia coli. J. Infect. Dis 1986; 154: 338–341
   PubMed Web of Science ®Google Scholar
• Munson P. J., Rodbard D. Ligand: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem 1980; 107: 220–239
   PubMed Web of Science ®Google Scholar
• O'Brien A. D., La Veck G. D., Thompson M. R., Formal S. B. Production of Shigella dysenteriae type 1–like cytotoxin by Escherichia coli. J. Infect. Dis 1982; 146: 763–769
   PubMed Web of Science ®Google Scholar
• O'Brien A. D., Tesh V. L., Donohue-Rolfe A., Jackson M. P., Olsnes S., Sandvig K., Lindberg A. A., Keusch G. T. Shiga toxin: Biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Topics Microbial. Immunol 1992; 180: 65–94
   PubMed Web of Science ®Google Scholar
• Obrig T. G., Del Vecchio P. J., Brown J. E., Moran T. P., Rowland B. M., Judge T. K., Rothman S. W. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect. Immun 1988; 56: 2373–2378
   PubMed Web of Science ®Google Scholar
• Obrig T. G., Louise C. B., Lingwood C. A., Boyd B., Barley-Maloney L., Daniel T. O. Endothelial heterogeneity in Shiga toxin receptors and responses. J. Biol. Chem 1993; 268: 15484–15488
   PubMed Web of Science ®Google Scholar
• Olsnes S., Reisbig R., Eiklid K. Subunit structure of Shigella cytotoxin. J. Biol. Chem 1981; 256: 8732–8738
   PubMed Web of Science ®Google Scholar
• Pellzzzari A., Pang H., Lingwood C. A. Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochemistry 1992; 31: 1363–1370
   PubMed Web of Science ®Google Scholar
• Raghupathy P., Date A., Shastry J. C. M., Sudarsanam A., Jadha M. Hemolytic uremic syndrome complicating shigella dysentery in South Indian children. Br. Med. J 1978; 1: 1518–1521
   PubMed Web of Science ®Google Scholar
• Ramotar K., Boyd B., Tyrrell G., Gariepy J., Lingwood C., Brunton J. Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron. Biochem. J 1990; 272: 805–811
   PubMed Web of Science ®Google Scholar
• Rietschel E. T., Brade L., Holst O., Kulshin V. A., Lindner B., Moran A. P., Schade U. F., Zahringer U., Brade H. Molecular structure of bacterial endotoxin in relation to bio-activity. Cellular und Molecular Aspects of Endotoxin Reactions, A. Nowotny, J. J. Spitzer, E. J. Ziegler. Elsevier Science Publishing Company. 1990; 15–32
   Google Scholar
• Strockbine N. A., Jackson M. P., Sung L. M., Holmes R. K., O'Brien A. D. Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1. J. Bacteriol 1988; 170: 1116–1122
   PubMedGoogle Scholar
• Strockbine N. A., Marques L. R. M., Newland J. W., Smith H. W., Holmes R. K., O'Brien A. D. Two toxin-converting phages from Escherichia coli 0157:H7 strain 033 encode antigenically distinct toxins with similar biological activities. Infect. Immun 1986; 53: 135–140
   PubMed Web of Science ®Google Scholar
• van de Kar N. C. A.J., Monnens L. A. H., Karmali M. A., van Hinsbergh V. W. M. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic sydrome. Blood 1992; 80: 2755–2764
   PubMed Web of Science ®Google Scholar
• Waddell T., Cohen A., Lingwood C. A. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. Proc. Natl. Acad. Sci. U.S.A 1990; 87: 7898–7901
   PubMedGoogle Scholar
• Wells J. W. Analysis and interpretation of binding at equilibrium. Receptor-Ligand Interactions: A Practical Approach, E. C. Hulme. Oxford University Press. 1992; 289–395
   Google Scholar
• Wojta J., Hoover R. L., Daniel T. O. Vascular origin determines plasminogen activator expression in human endothelial cells. J. Biol. Chem 1989; 264: 2846–2852
   PubMed Web of Science ®Google Scholar
• Zoja C., Remuzzi G. The pivotal role of the endothelial cell in the pathogenesis of HUS. The Hemolytic Syndromes/Thrombotic Thrombocytopenic Purpura, B. Kaplan, R. Trompeter, J. Moake. Marcel Dekker. 1992; 389–409
   Google Scholar